Research
Evidence, read off the primary source — page 4
No pattern-matched citations and no PMIDs pulled from memory. Every regulatory date, study, and label quote below was checked against its primary source before publication — see each article's reference list. 134 articles published so far.
How we verify a source
A PubMed citation is checked against PubMed's own record, not typed from recall. A regulatory page is read at the source and quoted, not paraphrased from a secondary blog. If a claim cannot be verified this way, it is softened or removed — never guessed.
Filter by topic
Showing 73–96 of 134 articles
Evidence review
GHRP-6: What the Evidence Actually Shows
GHRP-6 is sold as a bodybuilding GH secretagogue — but it's also the drug behind a real Cuban Phase III stroke trial. Here's what the evidence actually shows.
ReadEvidence review
Glutathione: What the Evidence Actually Shows
IV glutathione, oral glutathione, and NAC get sold as interchangeable — the trial evidence for each is genuinely different. Here's what actually holds up.
ReadEvidence review
Gonadorelin: What the Evidence Actually Shows
Gonadorelin once had real FDA-approved human products — both now discontinued. Here's its actual regulatory history and what its human evidence really supports.
ReadEvidence review
Hexarelin: What the Evidence Actually Shows
Hexarelin is marketed as the most potent, most 'cardioprotective' GH secretagogue. The cardioprotective evidence is real — but only in animals so far.
ReadEvidence review
Kisspeptin: What the Evidence Actually Shows
Kisspeptin has real, narrow reproductive-endocrinology research behind it — and FDA lists it as a significant safety risk. Here's what's actually studied.
ReadEvidence review
KLOW vs. GLOW Peptide: What Adding KPV Changes
KLOW is GLOW's three-peptide blend plus KPV. Here's what KPV's own evidence actually shows — and why the KLOW combination itself has never been tested.
ReadEvidence review
KPV Dosage: What Studies Actually Used — Not a Recommendation
KPV has no FDA-approved dose, and its own foundational colitis studies don't state a dose in the published abstract. Here's what's documented — not advice.
ReadEvidence review
Lanreotide: What the Evidence Actually Shows
Lanreotide is octreotide's longer-acting somatostatin-analog sibling. What the FDA label, the CLARINET trial, and the real product differences actually show.
ReadEvidence review
Liraglutide: What the Evidence Actually Shows
Liraglutide is a real, FDA-approved once-daily GLP-1 drug (Victoza, Saxenda) — and it just quietly went generic. Here's the real approval history.
ReadEvidence review
Mazdutide: What the Evidence Actually Shows
Mazdutide is already an approved drug in China, with real Phase 3 data behind it — but has zero regulatory presence in the U.S. Live-verified status.
ReadEvidence review
MOTS-c Dosage and Side Effects: What Studies Actually Used — Not a Recommendation
MOTS-c has no FDA-approved dose or human safety trial of the native peptide. Here's what mouse studies and the CB4211 analog trial report — not advice.
ReadEvidence review
NMN: What the Evidence Actually Shows
NMN is a massively-searched longevity supplement — and even its core absorption mechanism is scientifically disputed. Here's the real human trial record.
ReadEvidence review
Noopept: What the Evidence Actually Shows
Noopept isn't quite the peptide it's marketed as. Its own founding paper explains what it really is, and what the human evidence actually supports.
ReadEvidence review
Octreotide: What the Evidence Actually Shows
Octreotide suppresses growth hormone — the opposite of sermorelin and CJC-1295/ipamorelin. What the FDA label, the trials, and two real products actually show.
ReadEvidence review
Oral Semaglutide (the Wegovy Pill): What the Evidence Actually Shows
FDA approved a Wegovy tablet for weight management on December 22, 2025 — a third semaglutide product, distinct from Rybelsus and injectable Wegovy.
ReadEvidence review
Orforglipron: What the Evidence Actually Shows
Orforglipron, Eli Lilly's oral GLP-1 pill, is now FDA-approved as Foundayo. Here's what the live regulatory record and Phase 3 trial data actually show.
ReadEvidence review
Pinealon: What the Evidence Actually Shows
Pinealon is sold for cognitive support from the same Russian lab as Epitalon. Here's what a live PubMed search actually found for this molecule specifically.
ReadEvidence review
Pramlintide: What the Evidence Actually Shows
Pramlintide (Symlin) is a real, FDA-approved amylin analog, not a GLP-1 drug — and AstraZeneca has filed to discontinue it. Here's what a live check found.
ReadEvidence review
PT-141 (Bremelanotide): What the Evidence Actually Shows
Vyleesi (bremelanotide) has real Phase 3 trial data for one narrow use. Here's what the RECONNECT trials, FDA label, and male-use evidence actually show.
ReadEvidence review
PT-141 Dosage and Side Effects: What the Vyleesi Label Actually Says
Vyleesi has a real FDA-set dose and a real adverse-reaction table. Here's exactly what the label says — and why compounded PT-141 isn't reviewed against either.
ReadEvidence review
Selank: What the Evidence Actually Shows
Selank has real Russian human trial data behind its anxiolytic claims, but no U.S. approval and a live FDA-document discrepancy. Here's what's studied.
ReadEvidence review
Semax: What the Evidence Actually Shows
Semax has decades of Russian human research behind it, but no U.S. approval and a live FDA-document discrepancy. Here's what's actually studied.
ReadEvidence review
Sermorelin Before and After: What the Evidence Actually Shows You Can Expect
Sermorelin before and after claims are almost all anecdotal. Here's the actual week-by-week timeline data that exists — and what it doesn't show.
ReadEvidence review
Setmelanotide: What the Evidence Actually Shows
Setmelanotide (Imcivree) is a real, FDA-approved MC4 receptor agonist — but its label is genuinely narrow, for rare genetic obesity only.
Read
Nothing matches these filters
No article matches both the search text and the topic selected. Try clearing one of the two filters.